Should You Invest in Insmed Incorporated (INSM)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2024 investor letter.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 10,497,277 | $766,301,221 | +197% | 62.31% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,415,918 | $322,362,014 | +24% | 3.34% |
| 3. | 71,505,000 | $164,338,733 | +64% | 0.14% | |
| 4. | 62,024,000 | $142,283,056 | +83% | 3.87% | |
| 5. | Palo Alto Investors William Leland Edwards | 1,940,993 | $141,692,489 | -10% | 18.4% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.29 | 10,000 | Director | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | Director | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | Director | 15,900 | 2022-11-01 | Filing | |
| $17.53 | 20,000 | Director | 281,021 | 2022-10-31 | Filing | |
| $17.69 | 45,000 | Director | 98,265 | 2022-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.61 | 1,590 | Officer, Director | 233,924 | 2024-12-19 | Filing | |
| $69.71 | 5,240 | Officer, Director | 235,514 | 2024-12-19 | Filing | |
| $70.52 | 5,588 | Officer, Director | 384,960 | 2024-12-19 | Filing | |
| $69.65 | 13,162 | Officer, Director | 390,548 | 2024-12-19 | Filing | |
| $74.22 | 181 | Officer, Director | 233,924 | 2024-12-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,125,521 | $437,749,895 | 0% | |
| 2. | 11,492,282 | $356,145,819 | 0% | |
| 3. | 5,929,933 | $183,768,624 | 0% | |
| 4. | 5,091,614 | $157,789,126 | 0.01% | |
| 5. | 4,651,492 | $144,150,000 | 0.16% |
News See All
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
Do You Believe in the Growth Potential of Insmed (INSM)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
10 Best Performing NASDAQ Stocks in 2024
Fed's recent cut has resulted in significant outperformance in the tech sector, signaling a positive sentiment among investors.
7 Best Performing Long Term Stocks in 2024
After the latest 50 basis point rate cut by the Federal Reserve, the market has been performing well.
10 Best Performing Stocks in 2024
The Dow Jones Industrial Average has recently made headlines by closing above the 42,000 mark for the first time, a significant milestone that reflects a surge in investor confidence following a substantial...
16 Best Mid Cap Growth Stocks To Buy Now
Recent discussions among financial strategists emphasize the current stock market dynamics, particularly regarding the upcoming US elections.
Insmed Incorporated (INSM) Surged Following Positive Data For its Drug
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor letter. A copy of the fund can be downloaded here.
Insmed (INSM) Rose Due to Positive Trial Results
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
